Phase Bio Pharmaceuticals Inc PHAS
We take great care to ensure that the data presented and summarized in this overview for PhaseBio Pharmaceuticals Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PHAS
Top Purchases
Top Sells
About PHAS
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
Insider Transactions at PHAS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
May 19
2023
|
Nancy J Hutson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+9.09%
|
-
|
|
May 19
2023
|
Caroline M Loewy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
May 19
2023
|
Alex Sapir Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
May 19
2023
|
Edmund Harrigan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+27.78%
|
-
|
|
May 19
2023
|
William D. Humphries Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,538
+50.0%
|
-
|
|
May 19
2023
|
Clay Thorp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+9.27%
|
-
|
|
May 19
2023
|
Richard Van Den Broek Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+100.0%
|
-
|
|
Oct 25
2022
|
New Enterprise Associates 13 LP > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,784,109
-26.86%
|
$0
$0.15 P/Share
|
|
May 23
2022
|
Glen Burkhardt SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
11,248
-100.0%
|
$0
$0.79 P/Share
|
|
May 20
2022
|
John P Sharp Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,026
+8.39%
|
$0
$0.68 P/Share
|
|
May 20
2022
|
Jonathan Birchall Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
$0
$0.68 P/Share
|
|
May 20
2022
|
Kristopher Hanson SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
4,831
+36.34%
|
$0
$0.68 P/Share
|
|
May 20
2022
|
Glen Burkhardt SVP of Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
11,248
+50.0%
|
$0
$0.68 P/Share
|
|
May 20
2022
|
Jonathan P Mow Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,918
+7.61%
|
$0
$0.68 P/Share
|
|
May 20
2022
|
Susan Elizabeth Arnold SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
10,917
+20.93%
|
$0
$0.68 P/Share
|
|
Nov 19
2021
|
Glen Burkhardt SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
5,766
-100.0%
|
$11,532
$2.37 P/Share
|
|
Nov 19
2021
|
Glen Burkhardt SVP of Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
5,766
+50.0%
|
$11,532
$2.01 P/Share
|
|
Nov 19
2021
|
Kristopher Hanson SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+29.84%
|
$3,090
$2.01 P/Share
|
|
Nov 19
2021
|
John P Sharp Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,017
+3.27%
|
$4,034
$2.01 P/Share
|
|
Nov 19
2021
|
Susan Elizabeth Arnold SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
2,559
+7.78%
|
$5,118
$2.01 P/Share
|